Company intelligence / Profile preview

Boston Immune Technologies and Therapeutics

Winchester/Boston, Massachusetts, United Statesbostonimmunetech.com ↗

Ownership: Private
Development stage: Phase 1

Overview

BITT’s lead candidate BIR2101 targets TNFR2 and has entered Phase I clinical trials in oncology. The company has received NIH/NCI grants to support this trial. Preclinical programs include antagonist antibodies against CD40 for autoimmune/inflammatory indications and additional discovery-stage programs targeting CD30 and CD27. Early results in animal models suggest that combining TNFR2 antagonism with checkpoint inhibitors may improve cure rates in cancer models

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Monoclonal antibodies (mAbs)Antagonist antibodies
Industry: Biotech

Drug pipeline

5 assets

BITR2101

4 more assets in the full pipeline.

Request access →

Partnerships

BeiGene Ltd. – option/license arrangement on pipeline assets; investor/board representationOtsuka/MSRD – sponsored research/exclusivity agreement on the anti-CD40 program with right to negotiate acquisition/license/collaboration related to the assetNIH/NCI – grant funding for clinical development of lead asset BIR2101/TNFR2 antagonist

Beyond the preview

Go deeper on Boston Immune Technologies and Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Boston Immune Technologies and Therapeutics.

Explore the full profile